200 related articles for article (PubMed ID: 22695075)
21. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
22. Variations on brain microglial gene expression of MMPs, RECK, and TIMPs in inflammatory and non-inflammatory diseases in dogs.
Stein VM; Puff C; Genini S; Contioso VB; Baumgärtner W; Tipold A
Vet Immunol Immunopathol; 2011 Nov; 144(1-2):17-26. PubMed ID: 21802747
[TBL] [Abstract][Full Text] [Related]
23. Calcifying Cystic Odontogenic Tumour: immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN).
Prosdócimi FC; Rodini CO; Sogayar MC; Sousa SC; Xavier FC; Paiva KB
J Oral Pathol Med; 2014 Aug; 43(7):545-53. PubMed ID: 24484176
[TBL] [Abstract][Full Text] [Related]
24. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.
Chaffer CL; Dopheide B; McCulloch DR; Lee AB; Moseley JM; Thompson EW; Williams ED
Clin Exp Metastasis; 2005; 22(2):115-25. PubMed ID: 16086232
[TBL] [Abstract][Full Text] [Related]
25. The Obstructed Bladder: Expression of Collagen, Matrix Metalloproteinases, Muscarinic Receptors, and Angiogenic and Neurotrophic Factors in Patients With Benign Prostatic Hyperplasia.
Barbosa JABA; Reis ST; Nunes M; Ferreira YA; Leite KR; Nahas WC; Srougi M; Antunes AA
Urology; 2017 Aug; 106():167-172. PubMed ID: 28506859
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
27. Expression of matrix metalloproteinases-2, -9 and reversion-inducing cysteine-rich protein with Kazal motifs in gingiva in periodontal health and disease.
Liu N; Cao Y; Zhu G
Arch Oral Biol; 2017 Mar; 75():62-67. PubMed ID: 28043014
[TBL] [Abstract][Full Text] [Related]
28. rs3918242 variant genotype frequency and increased TIMP-2 and MMP-9 expression are positively correlated with cancer invasion in urinary bladder cancer.
Pençe S; Özbek E; Ozan Tiryakioğlu N; Ersoy Tunali N; Pençe HH; Tunali H
Cell Mol Biol (Noisy-le-grand); 2017 Sep; 63(9):46-52. PubMed ID: 28980922
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J
Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191
[TBL] [Abstract][Full Text] [Related]
30. Relationship between matrix metalloproteinases MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinases-1 and IL-5, IL-8 in nasal polyps.
Chen YS; Langhammer T; Westhofen M; Lorenzen J
Allergy; 2007 Jan; 62(1):66-72. PubMed ID: 17156344
[TBL] [Abstract][Full Text] [Related]
31. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
32. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma.
Qiao ZK; Li YL; Lu HT; Wang KL; Xu WH
World J Surg Oncol; 2013 Jan; 11():1. PubMed ID: 23281640
[TBL] [Abstract][Full Text] [Related]
33. An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines.
You J; Madigan MC; Rowe A; Sajinovic M; Russell PJ; Jackson P
Urol Oncol; 2012; 30(4):502-8. PubMed ID: 20864363
[TBL] [Abstract][Full Text] [Related]
34. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid.
Zlatarova ZI; Softova EB; Dokova KG; Messmer EM
Graefes Arch Clin Exp Ophthalmol; 2012 Mar; 250(3):425-31. PubMed ID: 21881840
[TBL] [Abstract][Full Text] [Related]
38. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
39. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
